← Leaderboards
Carl Neil Kraus
Arrevus, Inc.
$3,244,438
Attributed
$3,563,895
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2018–23$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,563,895 · 9
By mechanism
R41$2,527,834 · 8
R42$1,036,061 · 1
Top collaborators
- Vsevolod Y Polotsky2 shared
Others in their field
Other Emerging Leaders on “Mortality”
- Chanza Baytop · Westat, Inc.$271,217,917
- Beth Baseler · Leidos Biomedical Research, Inc.$87,027,148
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$56,084,949
- Greg Witham · Anp Technologies, Inc.$19,727,817
- Yunda Huang · Fred Hutchinson Cancer Center$19,033,873
- Barbara Halina Braffett · George Washington University$17,931,151
Research focus
MortalityDoseIn VivoResistanceMouse ModelSafetyInhibitor/AntagonistTreatment EfficacyMolecular ChaperonesNovel StrategiesAntimicrobial PeptideLeadEvaluationMulti-Drug ResistanceProteinsAntibioticsProgramsIn VitroAntibiotic ResistanceInsectaProlineInfectionMulti-Drug Resistant PathogenBacterial Proteins
Grant awards (10)
Leptin Receptor Agonist to Treat Sleep Disordered Breathing$319,944
R41 · FY2023 · HL · contact PI
Leptin Receptor Agonist as a Novel Prevention of Opioid Induced Respiratory Depression$318,971
R41 · FY2022 · DA · contact PI
Engineered adipokine receptor inhibitor for the treatment of triple negative breast cancer in obese patients$400,000
R41 · FY2021 · CA · contact PI
Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating sepsis$299,999
R41 · FY2020 · AI · contact PI
Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant bacteremia$738,606
R42 · FY2019 · AI · contact PI
Development of a predictive moderate throughput assay to screen novel Designer Proline-rich antimicrobial peptide Chaperone protein inhibitors (DPCs) against multi-drug resistant pathogen$299,248
R41 · FY2019 · AI · contact PI
Use of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating antibiotic resistant pneumonia$294,501
R41 · FY2019 · AI · contact PI
Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant wound infections$300,000
R41 · FY2018 · AI · contact PI
Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant bacteremia$297,455
R42 · FY2018 · AI · contact PI
Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant urinary tract infections$295,171
R41 · FY2018 · AI · contact PI